ECSP024210A - Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas - Google Patents

Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas

Info

Publication number
ECSP024210A
ECSP024210A EC2002004210A ECSP024210A ECSP024210A EC SP024210 A ECSP024210 A EC SP024210A EC 2002004210 A EC2002004210 A EC 2002004210A EC SP024210 A ECSP024210 A EC SP024210A EC SP024210 A ECSP024210 A EC SP024210A
Authority
EC
Ecuador
Prior art keywords
antibody molecules
specificity
same
necrosis factor
tumor necrosis
Prior art date
Application number
EC2002004210A
Other languages
English (en)
Inventor
Andrew George Popplewell
Diljeet Singh Athwal
Derek Thomas Brown
Andrew Neil Charles Weir
Andrew Paul Chapman
David John King
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP024210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of ECSP024210A publication Critical patent/ECSP024210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)

Abstract

Se describen moléculas de anticuerpo que contienen al menos una CDR procedente de un anticuerpo monoclonal de ratón que tiene especificidad por el TNF a humano. También se describe un anticuerpo de CDR injertadas en el que al menos una de las CDR es una CDR híbrida. También se describen secuencias de ADN que codifican las cadenas de las moléculas de anticuerpo, vectores, células huésped transformadas y usos de las moléculas de anticuerpo en el tratamiento de enfermedades mediadas por TNFap.
EC2002004210A 2000-06-06 2002-02-06 Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas ECSP024210A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products

Publications (1)

Publication Number Publication Date
ECSP024210A true ECSP024210A (es) 2002-05-23

Family

ID=9893121

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004210A ECSP024210A (es) 2000-06-06 2002-02-06 Moléculas de anticuerpo que tienen especificidad por el factor de necrosis tumoral alfa humano, y uso de las mismas

Country Status (42)

Country Link
US (4) US7012135B2 (es)
EP (4) EP1287140B1 (es)
JP (3) JP4064812B2 (es)
KR (1) KR20020047097A (es)
CN (1) CN1289671C (es)
AP (1) AP2092A (es)
AR (1) AR033978A1 (es)
AT (1) ATE451460T1 (es)
AU (1) AU783756B2 (es)
BE (1) BE2010C019I2 (es)
BG (1) BG66072B1 (es)
BR (2) BR0106682A (es)
CA (2) CA2707766C (es)
CY (6) CY1109889T1 (es)
CZ (1) CZ300737B6 (es)
DE (3) DE10192353T1 (es)
DK (4) DK2308975T3 (es)
EC (1) ECSP024210A (es)
ES (5) ES2600080T3 (es)
FR (1) FR10C0015I2 (es)
GB (2) GB0013810D0 (es)
HU (4) HU230553B1 (es)
IL (3) IL147992A0 (es)
IS (2) IS2808B (es)
LT (1) LT2308975T (es)
LU (1) LU91674I2 (es)
MX (1) MXPA01013440A (es)
MY (1) MY136603A (es)
NL (1) NL300982I9 (es)
NO (4) NO334808B1 (es)
NZ (1) NZ516596A (es)
OA (1) OA12282A (es)
PE (1) PE20020292A1 (es)
PL (2) PL218516B1 (es)
PT (4) PT2308975T (es)
RU (1) RU2303604C2 (es)
SI (3) SI2230308T1 (es)
SK (1) SK288343B6 (es)
TR (1) TR201900227T4 (es)
TW (2) TWI353358B (es)
WO (1) WO2001094585A1 (es)
ZA (1) ZA200200097B (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) * 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
ES2358505T3 (es) * 2002-03-20 2011-05-11 Ucb Pharma, S.A. Métodos para analizar isómeros de disulfuro de anticuerpos.
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
JP4418745B2 (ja) * 2002-05-28 2010-02-24 ユセベ ファルマ ソシエテ アノニム 抗体ｐｅｇ位置異性体、それを含む組成物及びその使用
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2311867A1 (en) 2002-10-29 2011-04-20 Anaphore, Inc. Trimeric binding proteins for trimeric cytokines
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
WO2004065417A2 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004074345A2 (en) * 2003-02-19 2004-09-02 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
SI1656455T1 (sl) * 2003-08-13 2012-12-31 Sandoz Ag Postopek za čiščenje rekombinantnih polipeptidov
JP5544063B2 (ja) * 2003-08-13 2014-07-09 サンド・アクチエンゲゼルシヤフト 組換えポリペプチドの生産のための発現ベクター、形質転換宿主細胞及び発酵方法
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
JP5757495B2 (ja) * 2005-05-16 2015-07-29 アッヴィ バイオテクノロジー リミテッド びらん性多発性関節炎の治療のためのｔｎｆ阻害剤の使用
CN101189265B (zh) * 2005-06-01 2012-07-04 米克罗麦特股份公司 抗il2抗体
EP1891110A2 (en) 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
EP2004231A4 (en) 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
WO2008153997A1 (en) * 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
EP2185188B1 (en) * 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
BRPI0907485A2 (pt) * 2008-02-05 2015-08-04 Delenex Therapeutics Ag Polipeptídeos de ligação a antígeno contra degeneração de cartilagem
ES2549903T3 (es) * 2008-05-07 2015-11-03 Argos Therapeutics, Inc. Anticuerpos humanizados contra interferón alfa humano
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
EP3964526A1 (en) 2008-06-25 2022-03-09 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
NZ593905A (en) * 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
CA2774692C (en) 2009-09-24 2017-12-19 Ucb Pharma S.A. Bacterial strain for recombinant protein expression, having protease deficient degp retaining chaperone activity, and knocked out tsp and ptr genes
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc ON CD52 MONOCLONAL ANTIBODIES
BR112012022338A2 (pt) 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais direcionados a cd20
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP2714912B1 (en) 2011-06-01 2018-05-02 Intrexon Actobiotics NV Polycistronic expression system for bacteria
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
SMT201800068T1 (it) 2011-07-13 2018-03-08 Ucb Biopharma Sprl Ceppo ospite batterico che esprime dsbc ricombinante
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
HUE038830T2 (hu) 2011-09-23 2018-11-28 Intrexon Actobiotics Nv Módosított gram-pozitív baktériumok és alkalmazásaik
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
ES3046837T3 (en) 2014-12-22 2025-12-02 UCB Biopharma SRL Method of protein manufacture
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3658192B1 (en) 2017-12-01 2021-04-28 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
JP7525499B2 (ja) 2019-01-31 2024-07-30 ヌマブ セラピューティクス アクチェンゲゼルシャフト ＴＮＦα及びＩＬ－１７Ａに対する特異性を有する多重特異性抗体、ＩＬ－１７Ａを標的とする抗体、及びそれらの使用方法
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022172085A2 (en) 2021-02-15 2022-08-18 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
US20250368732A1 (en) 2021-09-24 2025-12-04 Xbrane Biopharma Ab Dna constructs and host cells for expressing recombinant protein
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
IL328082A (en) 2023-11-06 2026-06-01 Momenta Pharmaceuticals Inc Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
CA2163032C (en) * 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
IL195085A0 (en) 2009-08-03
ATE451460T1 (de) 2009-12-15
CY2010011I2 (el) 2012-01-25
EP3059314A1 (en) 2016-08-24
LT2308975T (lt) 2016-11-10
BR0106682A (pt) 2002-05-14
FR10C0015I2 (fr) 2011-12-30
EP2308975B1 (en) 2016-08-10
AP2002002690A0 (en) 2002-12-31
ES2230975A1 (es) 2005-05-01
NO2014026I1 (no) 2014-10-23
EP2230308A1 (en) 2010-09-22
US7012135B2 (en) 2006-03-14
GB2366800A (en) 2002-03-20
AR033978A1 (es) 2004-01-21
US7186820B2 (en) 2007-03-06
SI1287140T1 (sl) 2010-04-30
HUP1600483A2 (es) 2002-10-28
CY2010011I1 (el) 2012-01-25
SK288343B6 (sk) 2016-04-01
DK2308975T3 (da) 2016-10-31
CY1109889T1 (el) 2012-01-25
BRPI0106682B8 (pt) 2021-05-25
AP2092A (en) 2010-02-28
HUP0202346A2 (en) 2002-10-28
CY2019018I1 (el) 2020-05-29
IS2808B (is) 2012-09-15
ES2600080T3 (es) 2017-02-07
HK1148776A1 (en) 2011-09-16
JP5185143B2 (ja) 2013-04-17
CN1289671C (zh) 2006-12-13
NO20131316L (no) 2002-04-08
BRPI0106682B1 (pt) 2020-10-13
HUP0202346A3 (en) 2004-11-29
LU91674I9 (es) 2019-01-03
CN1383450A (zh) 2002-12-04
FR10C0015I1 (es) 2010-04-16
CY1121173T1 (el) 2020-05-29
DK2230308T3 (da) 2013-05-06
GB2366800B (en) 2005-01-19
IS6217A (is) 2002-01-03
PL353960A1 (en) 2003-12-15
CA2380298C (en) 2010-09-28
HUS1700013I1 (hu) 2017-08-28
IL147992A0 (en) 2002-09-12
ES2403217T3 (es) 2013-05-16
JP2003535591A (ja) 2003-12-02
IL147992A (en) 2009-06-15
BG106278A (bg) 2002-12-29
CA2380298A1 (en) 2001-12-13
SI2308975T1 (sl) 2016-11-30
PT2230308E (pt) 2013-05-03
HK1051385A1 (en) 2003-08-01
ES2337763T3 (es) 2010-04-29
EP2230308B1 (en) 2013-01-23
NO20020554D0 (no) 2002-02-04
TW200817430A (en) 2008-04-16
AU6051101A (en) 2001-12-17
TR201900227T4 (tr) 2019-02-21
PT1287140E (pt) 2010-03-08
LU91674I2 (fr) 2010-05-31
US20020151682A1 (en) 2002-10-17
NO2014026I2 (no) 2018-02-14
DK3059314T3 (en) 2019-02-18
EP1287140B1 (en) 2009-12-09
PL212738B1 (pl) 2012-11-30
KR20020047097A (ko) 2002-06-21
GB0013810D0 (en) 2000-07-26
HUP1600016A2 (en) 2002-10-28
NO20020554L (no) 2002-04-08
PE20020292A1 (es) 2002-05-08
US20030026805A1 (en) 2003-02-06
JP4476989B2 (ja) 2010-06-09
PT3059314T (pt) 2019-02-01
DK1287140T3 (da) 2010-04-19
NO341218B1 (no) 2017-09-11
BG66072B1 (bg) 2011-01-31
ES2230975B2 (es) 2007-04-16
DE10192353T1 (de) 2003-05-22
NL300982I1 (es) 2019-05-01
AU783756B2 (en) 2005-12-01
MXPA01013440A (es) 2003-09-04
SI2230308T1 (sl) 2013-06-28
US7402662B2 (en) 2008-07-22
NO20160694A1 (no) 2002-04-08
CZ300737B6 (cs) 2009-07-29
US20060233800A1 (en) 2006-10-19
IS3016B (is) 2019-10-15
NZ516596A (en) 2004-07-30
CY2019018I2 (el) 2020-05-29
CY1114143T1 (el) 2016-07-27
PL399351A1 (pl) 2012-12-17
RU2303604C2 (ru) 2007-07-27
HU230669B1 (hu) 2017-07-28
WO2001094585A1 (en) 2001-12-13
OA12282A (en) 2006-05-11
EP2308975A1 (en) 2011-04-13
NO339282B1 (no) 2016-11-21
SK3152002A3 (en) 2002-07-02
JP2007105043A (ja) 2007-04-26
HU230553B1 (hu) 2016-11-28
DE122010000027I1 (de) 2010-08-12
EP3059314B1 (en) 2018-10-24
JP2009171966A (ja) 2009-08-06
MY136603A (en) 2008-10-31
CZ2002837A3 (cs) 2002-05-15
EP1287140A1 (en) 2003-03-05
DE60140738D1 (de) 2010-01-21
NL300982I9 (nl) 2019-05-06
CA2707766C (en) 2013-05-21
CY1118220T1 (el) 2017-06-28
GB0128386D0 (en) 2002-01-16
BE2010C019I2 (es) 2020-08-20
US20080269465A1 (en) 2008-10-30
TWI316088B (en) 2009-10-21
ES2707714T3 (es) 2019-04-04
US7977464B2 (en) 2011-07-12
NO334808B1 (no) 2014-06-02
PT2308975T (pt) 2016-11-14
ZA200200097B (en) 2003-01-06
TWI353358B (en) 2011-12-01
CA2707766A1 (en) 2001-12-13
HU230561B1 (hu) 2016-12-28
PL218516B1 (pl) 2014-12-31
JP4064812B2 (ja) 2008-03-19

Similar Documents

Publication Publication Date Title
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
DE60237778D1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
NL300920I2 (nl) inotuzumab ozogamicine
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
PE20050712A1 (es) Anticuerpos rg1
EA200800094A1 (ru) Антитела cd19 и их использование
EP1536006A4 (en) CANCER-ANIMALS AND THEIR USE
EP0972054A4 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака
DE602004029394D1 (de) Antikörper variable region eines monoklonalen antikörpers gegen den humanen tumor nekrose faktor-alpha und dafür kodierendes gen
UY26170A1 (es) Antigeno (c42) asociados a tumores
AR023794A1 (es) Antigeno asociado con tumores
UY26127A1 (es) Antígeno asociado con tumores